Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to $91.6 million.

  • Xeris Biopharma Holdings' Cash & Equivalents rose 5464.28% to $91.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $91.6 million, marking a year-over-year increase of 5464.28%. This contributed to the annual value of $71.6 million for FY2024, which is 618.54% up from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Cash & Equivalents stood at $91.6 million for Q3 2025, which was up 5464.28% from $59.3 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Cash & Equivalents high stood at $122.0 million for Q4 2022, and its period low was $46.1 million during Q3 2023.
  • For the 5-year period, Xeris Biopharma Holdings' Cash & Equivalents averaged around $70.8 million, with its median value being $62.7 million (2024).
  • Per our database at Business Quant, Xeris Biopharma Holdings' Cash & Equivalents surged by 8130.55% in 2022 and then tumbled by 5157.33% in 2023.
  • Xeris Biopharma Holdings' Cash & Equivalents (Quarter) stood at $67.3 million in 2021, then surged by 81.31% to $122.0 million in 2022, then tumbled by 44.7% to $67.4 million in 2023, then increased by 6.19% to $71.6 million in 2024, then increased by 27.89% to $91.6 million in 2025.
  • Its last three reported values are $91.6 million in Q3 2025, $59.3 million for Q2 2025, and $58.4 million during Q1 2025.